Pacer Advisors Inc. Sells 237 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Pacer Advisors Inc. decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,459 shares of the medical research company’s stock after selling 237 shares during the quarter. Pacer Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $13,513,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of TMO. Halpern Financial Inc. raised its stake in Thermo Fisher Scientific by 307.7% during the third quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 40 shares in the last quarter. Coppell Advisory Solutions LLC purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at $33,000. Live Oak Investment Partners purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $36,000. Tyler Stone Wealth Management purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at $37,000. Finally, Indiana Trust & Investment Management CO purchased a new stake in shares of Thermo Fisher Scientific in the third quarter valued at $38,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock valued at $28,513,384 in the last three months. 0.32% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Royal Bank of Canada raised their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $575.00 price target on the stock. Robert W. Baird reaffirmed an “outperform” rating and issued a $670.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, December 14th. TheStreet upgraded shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Finally, Citigroup began coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price on the stock. Five investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $599.00.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $569.22 on Wednesday. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $217.05 billion, a P/E ratio of 36.84, a PEG ratio of 2.41 and a beta of 0.80. The company has a 50 day moving average price of $563.78 and a 200 day moving average price of $519.45.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same period last year, the firm posted $5.40 EPS. Thermo Fisher Scientific’s revenue for the quarter was down 4.9% compared to the same quarter last year. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be given a dividend of $0.39 per share. The ex-dividend date is Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.